Medannex Advances First ANAX1 Antagonist With Modular Cancer Trial Approach

Emerging Company Profile: The Scottish biotech is the only firm targeting the ANAX1 protein with plans to initiate a modular Phase I trial that could look at multiple tumor types before expanding to the autoimmune space.